{"id":"e2007-perampanel","safety":{"commonSideEffects":[{"rate":"20-30","effect":"Dizziness"},{"rate":"15-25","effect":"Somnolence"},{"rate":"10-15","effect":"Headache"},{"rate":"10-15","effect":"Fatigue"},{"rate":"5-10","effect":"Irritability"},{"rate":"5-10","effect":"Ataxia"},{"rate":"5-10","effect":"Aggression/behavioral changes"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Perampanel selectively blocks AMPA-type glutamate receptors on the neuronal cell membrane, which are key mediators of excitatory synaptic transmission. By antagonizing these receptors, it reduces excessive neuronal firing and seizure activity. This mechanism differs from other antiepileptic drugs and provides an alternative approach to seizure control.","oneSentence":"Perampanel is a non-competitive AMPA receptor antagonist that reduces glutamate-mediated excitatory neurotransmission in the brain.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:10:36.173Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Partial-onset seizures (adjunctive therapy)"},{"name":"Generalized tonic-clonic seizures (adjunctive therapy)"}]},"trialDetails":[{"nctId":"NCT04015141","phase":"PHASE2","title":"A Study to Evaluate Efficacy and Safety of Perampanel Administered as an Adjunctive Therapy in Pediatric Participants With Childhood Epilepsy","status":"RECRUITING","sponsor":"Eisai Inc.","startDate":"2019-05-31","conditions":"Pediatric Epileptic Syndrome, Partial-onset Seizures","enrollment":100},{"nctId":"NCT02307578","phase":"","title":"An Extended Access Program (EAP) for Perampanel","status":"NO_LONGER_AVAILABLE","sponsor":"Eisai Inc.","startDate":"","conditions":"Primary Generalized Tonic-Clonic or Partial Onset Seizures, Lennox Gastaut Syndrome","enrollment":""},{"nctId":"NCT05533814","phase":"PHASE4","title":"A Study to Evaluate the Efficacy and Safety of Perampanel Monotherapy in Untreated Participants With Focal Onset Seizures With or Without Focal to Bilateral Tonic-clonic Seizures","status":"COMPLETED","sponsor":"Eisai Korea Inc.","startDate":"2022-10-19","conditions":"Epilepsy","enrollment":125},{"nctId":"NCT04497142","phase":"PHASE1, PHASE2","title":"Effect of Perampanel on Peritumoral Hyperexcitability in HGG","status":"COMPLETED","sponsor":"Dana-Farber Cancer Institute","startDate":"2020-11-05","conditions":"Glioma, Malignant, Surgery, Seizures","enrollment":12},{"nctId":"NCT02914314","phase":"PHASE2","title":"Pharmacokinetic Study With an Oral Suspension of Perampanel as Adjunctive Therapy in Pediatric Subjects With Epilepsy","status":"COMPLETED","sponsor":"Eisai Inc.","startDate":"2017-02-20","conditions":"Epilepsy","enrollment":26},{"nctId":"NCT04202159","phase":"","title":"A Study to Evaluate the Effectiveness of Perampanel as Only Add-on Treatment in Participants With Primary or Secondarily Generalized Tonic-clonic Seizures","status":"COMPLETED","sponsor":"Eisai GmbH","startDate":"2020-01-21","conditions":"Seizures","enrollment":187},{"nctId":"NCT04650204","phase":"PHASE4","title":"Perampanel for the Reduction of Seizure Frequency in Patients With High-grade Glioma and Focal Epilepsy","status":"TERMINATED","sponsor":"Mayo Clinic","startDate":"2020-12-04","conditions":"Intractable Epilepsy, Malignant Glioma, Seizure Disorder","enrollment":4},{"nctId":"NCT02849626","phase":"PHASE3","title":"Perampanel as Adjunctive Therapy in Pediatrics With Partial Onset Seizures or Primary Generalized Tonic Clonic Seizures","status":"COMPLETED","sponsor":"Eisai Inc.","startDate":"2016-11-16","conditions":"Partial-Onset or Primary Generalized Tonic-Clonic Seizures","enrollment":180},{"nctId":"NCT03288129","phase":"PHASE4","title":"Study to Evaluate the Efficacy and Safety of Perampanel as Monotherapy or First Adjunctive Therapy in Subjects With Partial Onset Seizures With or Without Secondarily Generalized Seizures or With Primary Generalized Tonic-Clonic Seizures","status":"COMPLETED","sponsor":"Eisai Inc.","startDate":"2017-08-23","conditions":"Partial Onset Seizures, Secondarily Generalized Seizures, Primary Generalized Tonic-Clonic Seizures","enrollment":54},{"nctId":"NCT02834793","phase":"PHASE3","title":"Study of Perampanel as Adjunctive Treatment for Inadequately Controlled Seizures Associated With Lennox-Gastaut Syndrome","status":"TERMINATED","sponsor":"Eisai Inc.","startDate":"2016-12-13","conditions":"Lennox-Gastaut Syndrome (LGS)","enrollment":101},{"nctId":"NCT03201900","phase":"PHASE3","title":"Study for Verification of Efficacy and Safety for Perampanel Monotherapy in Untreated Participants With Partial Onset Seizures (Including Secondarily Generalized Seizures (FREEDOM Study)","status":"COMPLETED","sponsor":"Eisai Co., Ltd.","startDate":"2017-06-28","conditions":"Partial Onset Seizures","enrollment":91},{"nctId":"NCT01618695","phase":"PHASE3","title":"A Study With an Open-label Extension Phase to Evaluate the Efficacy and Safety of Perampanel (E2007) Administered as an Adjunctive Therapy in Subjects With Refractory Partial-onset Seizures","status":"COMPLETED","sponsor":"Eisai Co., Ltd.","startDate":"2012-05-15","conditions":"Partial-onset Seizures","enrollment":940},{"nctId":"NCT03836924","phase":"","title":"A Study to Assess Safety and Efficacy of Perampanel in Indian Participants as an Adjunctive Treatment in Partial Onset Seizures With or Without Secondary Generalized Seizures in Participants With Epilepsy Aged 12 Years or Older","status":"COMPLETED","sponsor":"Eisai Pharmaceuticals India Pvt. Ltd","startDate":"2019-02-18","conditions":"Partial Onset Seizures, Epilepsy","enrollment":200},{"nctId":"NCT03754582","phase":"PHASE2","title":"A Study of Intravenous Perampanel in Japanese Participants With Epilepsy","status":"COMPLETED","sponsor":"Eisai Co., Ltd.","startDate":"2018-11-27","conditions":"Epilepsy, Seizures","enrollment":21},{"nctId":"NCT01871233","phase":"","title":"An Extended Access Program for Perampanel","status":"NO_LONGER_AVAILABLE","sponsor":"Eisai Inc.","startDate":"","conditions":"Partial Onset Seizures","enrollment":""},{"nctId":"NCT02131467","phase":"PHASE1, PHASE2","title":"Safety and Tolerability of Perampanel in Cervical Dystonia","status":"COMPLETED","sponsor":"University Health Network, Toronto","startDate":"2017-09-01","conditions":"Cervical Dystonia","enrollment":25},{"nctId":"NCT04257604","phase":"","title":"A Study of Perampanel as Add-on Therapy in Adult and Adolescent Participants With Focal Seizures","status":"COMPLETED","sponsor":"Eisai Limited","startDate":"2016-01-03","conditions":"Partial Seizures","enrollment":243},{"nctId":"NCT02726074","phase":"PHASE4","title":"Trial Evaluating the Efficacy and Safety of Perampanel Added to Monotherapy in Participants With Partial Onset Seizures With or Without Secondary Generalization","status":"COMPLETED","sponsor":"Eisai Korea Inc.","startDate":"2016-05-03","conditions":"Epilepsy","enrollment":106},{"nctId":"NCT04230044","phase":"","title":"A Study to Evaluate the Safety and Efficacy of Fycompa® (Perampanel) as Add-on Therapy in Participants With Epilepsy","status":"COMPLETED","sponsor":"Eisai Co., Ltd.","startDate":"2016-04-11","conditions":"Epilepsy, Partial-onset Seizures","enrollment":117},{"nctId":"NCT00699972","phase":"PHASE3","title":"Evaluating the Efficacy and Safety of E2007 (Perampanel) Given as Adjunctive Therapy in Subjects With Refractory Partial Seizures","status":"COMPLETED","sponsor":"Eisai Inc.","startDate":"2008-04-30","conditions":"Refractory Partial Seizures","enrollment":390},{"nctId":"NCT01161524","phase":"PHASE2","title":"A Study With an Open-label Extension Phase to Evaluate the Effect of Perampanel (E2007) on Cognition, Growth, Safety, Tolerability, and Pharmacokinetics in Adolescents","status":"COMPLETED","sponsor":"Eisai Inc.","startDate":"2010-09","conditions":"Epilepsy","enrollment":133},{"nctId":"NCT03780907","phase":"PHASE2","title":"Safety and Pharmacokinetics Study of E2007 to Treat Partial and Generalised Seizures in People With Epilepsy","status":"COMPLETED","sponsor":"Eisai Co., Ltd.","startDate":"2003-02-14","conditions":"Epilepsy","enrollment":18},{"nctId":"NCT03399734","phase":"PHASE1","title":"Bioequivalence Study Between a 4-mg Dose of Fine Granules of Perampanel and a 4-mg Tablet of Perampanel in Healthy Japanese Subjects","status":"COMPLETED","sponsor":"Eisai Co., Ltd.","startDate":"2017-12-18","conditions":"Healthy Participants","enrollment":24},{"nctId":"NCT03376997","phase":"PHASE1","title":"Study to Evaluate Bioavailability of a Single 12 mg Dose of Perampanel for Three Intravenous Infusion Durations Relative to a Single 12 mg Perampanel Oral Tablet in Healthy Subjects","status":"COMPLETED","sponsor":"Eisai Inc.","startDate":"2017-11-08","conditions":"Healthy Participants","enrollment":48},{"nctId":"NCT00566462","phase":"PHASE2","title":"Assessment of Perampanel (E2007) on Synaptic Dopamine in Mild-moderate PD Patients: A Pilot Study With [^123I]-IBZM SPECT","status":"TERMINATED","sponsor":"Eisai Inc.","startDate":"2007-10","conditions":"Parkinson's Disease","enrollment":1},{"nctId":"NCT00903786","phase":"PHASE2","title":"A Long-term Extension Study of E2007 in Patients With Refractory Partial Seizures Uncontrolled With Other Anti-Epileptic Drugs (AEDs)","status":"COMPLETED","sponsor":"Eisai Co., Ltd.","startDate":"2009-06-17","conditions":"Refractory Partial Seizures","enrollment":21},{"nctId":"NCT03424564","phase":"PHASE1","title":"Pharmacokinetic Study of Perampanel in Chinese Healthy Subjects","status":"COMPLETED","sponsor":"Eisai Co., Ltd.","startDate":"2018-03-20","conditions":"Healthy Subjects","enrollment":44},{"nctId":"NCT02427607","phase":"PHASE3","title":"An Open-label Extension Study to Evaluate the Safety and Tolerability of Perampanel (E2007) Administered as an Adjunctive Therapy in Epilepsy Subjects","status":"COMPLETED","sponsor":"Eisai Co., Ltd.","startDate":"2015-05-12","conditions":"Epilepsy","enrollment":7},{"nctId":"NCT01393743","phase":"PHASE3","title":"A Efficacy and Safety Study of Adjunctive Perampanel in Primary Generalized Tonic Clonic Seizures","status":"COMPLETED","sponsor":"Eisai Inc.","startDate":"2011-09","conditions":"Seizure Disorder Generalized Tonic Clonic","enrollment":163},{"nctId":"NCT02736162","phase":"","title":"Study to Investigate Dosage, Efficacy, and Safety of Perampanel Given as Monotherapy in Patients With Epilepsy","status":"COMPLETED","sponsor":"Eisai Inc.","startDate":"2016-04","conditions":"Epilepsy, Partial-Onset Seizures, Primary Generalized Tonic-Clonic Seizures","enrollment":61},{"nctId":"NCT01527006","phase":"PHASE2","title":"Pharmacokinetics, Efficacy, and Safety of Perampanel Oral Suspension on Seizure Frequency in Pediatric Subjects Maintained on One to Three Stable Antiepileptic Drugs","status":"COMPLETED","sponsor":"Eisai Inc.","startDate":"2012-01","conditions":"Central Nervous System","enrollment":63},{"nctId":"NCT00735397","phase":"PHASE3","title":"Evaluation of the Efficacy and Safety of E2007 (Perampanel) Given as Adjunctive Therapy in Subjects With Refractory Partial Seizures","status":"COMPLETED","sponsor":"Eisai Inc.","startDate":"2008-10","conditions":"Epilepsy","enrollment":1218},{"nctId":"NCT02511873","phase":"PHASE2","title":"Fycompa in Subjects With Small Fiber Neuropathy (SFN)","status":"UNKNOWN","sponsor":"PNA Center for Neurological Research","startDate":"2016-01","conditions":"Neuropathy, Small Fiber","enrollment":30},{"nctId":"NCT00505622","phase":"PHASE3","title":"Evaluation of the Long-term Safety, Tolerability, and Efficacy of Perampanel (E2007) as an Adjunctive Therapy in Levodopa Treated Parkinson's Disease Subjects With Motor Fluctuations","status":"TERMINATED","sponsor":"Eisai Limited","startDate":"2007-07","conditions":"Parkinson's Disease","enrollment":328},{"nctId":"NCT00700310","phase":"PHASE3","title":"Evaluating Efficacy and Safety of E2007 (Perampanel) Given as Adjunctive Therapy in Subjects With Refractory Partial Seizures","status":"COMPLETED","sponsor":"Eisai Inc.","startDate":"2008-08","conditions":"Refractory Partial Seizures","enrollment":712},{"nctId":"NCT00592904","phase":"PHASE2, PHASE3","title":"Evaluating E2007 (Perampanel) in Patients With Painful Diabetic Neuropathy (PDN) or Post-Herpetic Neuralgia (PHN)","status":"COMPLETED","sponsor":"Eisai Inc.","startDate":"2008-01","conditions":"Neuralgia","enrollment":262},{"nctId":"NCT00368472","phase":"PHASE2","title":"4-Year Open-Label Extension Phase of the Parallel-Group Study of E2007 in Patients With Refractory Partial Seizures","status":"COMPLETED","sponsor":"Eisai Inc.","startDate":"2006-10","conditions":"Epilepsy","enrollment":138},{"nctId":"NCT00144690","phase":"PHASE2","title":"E2007 Given as Adjunctive Therapy in Patients With Refractory Partial Seizures","status":"COMPLETED","sponsor":"Eisai Inc.","startDate":"2005-03","conditions":"Epilepsy","enrollment":""},{"nctId":"NCT00286897","phase":"PHASE3","title":"The Efficacy, Safety and Tolerability of E2007 in Levodopa Treated Parkinson's Disease Patients With Motor Fluctuations","status":"COMPLETED","sponsor":"Eisai Limited","startDate":"2006-02","conditions":"Parkinson's Disease","enrollment":702},{"nctId":"NCT02116907","phase":"PHASE1","title":"An Open-Label, Single-Dose Study to Determine the Metabolism and Elimination of 14C-Perampanel in Healthy Male Subjects","status":"COMPLETED","sponsor":"Eisai Inc.","startDate":"2014-05","conditions":"Healthy Subjects","enrollment":7},{"nctId":"NCT00154063","phase":"PHASE2","title":"Efficacy and Safety Study of E2007 in Migraine Prophylaxis","status":"COMPLETED","sponsor":"Eisai Inc.","startDate":"2005-01","conditions":"Migraine Prophylaxis","enrollment":206},{"nctId":"NCT00165789","phase":"PHASE2","title":"A Study to Explore the Safety And Tolerability of Doses of E2007 Up to a Maximum of 8 mg In Patients With Parkinson's Disease Who Experience End-of-Dose Wearing Off Motor Fluctuations","status":"COMPLETED","sponsor":"Eisai Inc.","startDate":"2005-09","conditions":"Parkinson's Disease","enrollment":75},{"nctId":"NCT01172379","phase":"PHASE2","title":"A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study of the Safety, Tolerability and Efficacy of E2007 in Parkinson's Disease Patients With \"Wearing Off\" Motor Fluctuations and \"On\" Period Dyskinesias","status":"COMPLETED","sponsor":"Eisai Limited","startDate":"2004-05","conditions":"Parkinson's Disease","enrollment":2},{"nctId":"NCT00505284","phase":"PHASE2, PHASE3","title":"An Evaluation of the Efficacy and Safety of E2007 in Patients With Painful Diabetic Neuropathy","status":"COMPLETED","sponsor":"Eisai Inc.","startDate":"2007-06","conditions":"Diabetic Neuropathy","enrollment":352},{"nctId":"NCT00699582","phase":"PHASE3","title":"To Evaluate The Efficacy and Safety of E2007 (Perampanel) Given as Adjunctive Therapy in Subjects With Refractory Partial Seizures","status":"COMPLETED","sponsor":"Eisai Inc.","startDate":"2008-05","conditions":"Refractory Partial Seizures","enrollment":389},{"nctId":"NCT00360308","phase":"PHASE3","title":"Efficacy, Safety and Tolerability of E2007 in Levodopa Treated Parkinson's Disease Patients With Motor Fluctuations","status":"TERMINATED","sponsor":"Eisai Limited","startDate":"2006-11","conditions":"Parkinson's Disease","enrollment":723},{"nctId":"NCT00360412","phase":"PHASE3","title":"A Study of E2007 as an Adjunctive Therapy in Levodopa Treated Parkinson's Disease Patients With Motor Fluctuations","status":"TERMINATED","sponsor":"Eisai Inc.","startDate":"2006-10","conditions":"Parkinson's Disease","enrollment":997},{"nctId":"NCT00416195","phase":"PHASE2","title":"Exploring the Safety And Tolerability of Doses of E2007 up to a Maximum of 12 mg In Patients With Refractory Partial Seizures","status":"COMPLETED","sponsor":"Eisai Co., Ltd.","startDate":"2006-12","conditions":"Epilepsy","enrollment":48},{"nctId":"NCT01634360","phase":"PHASE2","title":"Long-Term Safety, Tolerability and Efficacy in Perampanel Treated Parkinson's Disease Patients With Motor Fluctuations","status":"TERMINATED","sponsor":"Eisai Inc.","startDate":"2004-11","conditions":"Parkinson's Disease","enrollment":185},{"nctId":"NCT00451633","phase":"PHASE2","title":"The Effect Of E2007 On Pharmacodynamic Responses To Levodopa Among Patients With Parkinson's Disease Who Experience Dyskinesia And Motor Fluctuations","status":"WITHDRAWN","sponsor":"Eisai Inc.","startDate":"2007-03","conditions":"Parkinson's Disease","enrollment":""},{"nctId":"NCT00368108","phase":"PHASE3","title":"Efficacy, Safety, and Tolerability of E2007 in Levodopa Treated Parkinson's Disease Patients With Motor Fluctuations","status":"COMPLETED","sponsor":"Eisai Inc.","startDate":"2006-08","conditions":"Parkinson's Disease","enrollment":752},{"nctId":"NCT00592774","phase":"PHASE2","title":"Dose-Tolerability Titration Study to Evaluate The Efficacy And Safety Of Perampanel (E2007) In Patients With Post-Herpetic Neuralgia (PHN)","status":"COMPLETED","sponsor":"Eisai Inc.","startDate":"2008-01","conditions":"Neuralgia","enrollment":146},{"nctId":"NCT00427011","phase":"PHASE2","title":"A Study of E2007 In Patients With Parkinson's Disease","status":"TERMINATED","sponsor":"Eisai Inc.","startDate":"2007-02","conditions":"Parkinson's Disease","enrollment":25},{"nctId":"NCT00849212","phase":"PHASE2","title":"An add-on Study of E2007 in Patients With Refractory Partial Seizures Uncontrolled With Other Anti-epileptic Drugs (AEDs)","status":"COMPLETED","sponsor":"Eisai Co., Ltd.","startDate":"2009-04","conditions":"Refractory Partial Seizures","enrollment":30}],"_emaApprovals":[],"_faersSignals":[{"count":6,"reaction":"DIZZINESS"},{"count":6,"reaction":"STATUS EPILEPTICUS"},{"count":5,"reaction":"AGGRESSION"},{"count":4,"reaction":"ACUTE PSYCHOSIS"},{"count":3,"reaction":"CONTUSION"},{"count":3,"reaction":"GRAND MAL CONVULSION"},{"count":3,"reaction":"HEADACHE"},{"count":3,"reaction":"NAUSEA"},{"count":3,"reaction":"PNEUMONIA"},{"count":3,"reaction":"URINARY TRACT INFECTION"}],"_approvalHistory":[],"publicationCount":1179,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["perampanel","Perampanel"],"phase":"phase_3","status":"active","brandName":"E2007 (perampanel)","genericName":"E2007 (perampanel)","companyName":"Eisai Inc.","companyId":"eisai-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Perampanel is a non-competitive AMPA receptor antagonist that reduces glutamate-mediated excitatory neurotransmission in the brain. Used for Partial-onset seizures (adjunctive therapy), Generalized tonic-clonic seizures (adjunctive therapy).","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}